Log in
NASDAQ:BPTH

Bio-Path Stock Forecast, Price & News

$3.35
-0.04 (-1.18 %)
(As of 12/3/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.32
Now: $3.35▼
$3.43
50-Day Range
$3.21
MA: $3.65▼
$5.26
52-Week Range
$2.92
Now: $3.35▼
$8.65
Volume73,271 shs
Average Volume357,618 shs
Market Capitalization$15.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Bio-Path logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.37 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPTH
Previous Symbol
CUSIPN/A
CIK1133818
Webwww.biopathholdings.com
Phone832-742-1357
Employees9

Debt

Debt-to-Equity RatioN/A
Current Ratio10.03
Quick Ratio10.03

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales380.39
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.90 per share
Price / Book1.16

Profitability

EPS (Most Recent Fiscal Year)($3.24)
Net Income$-8,600,000.00
Net MarginsN/A
Return on Equity-62.72%
Return on Assets-57.14%

Miscellaneous

Outstanding Shares4,542,000
Market Cap$15.22 million
Next Earnings Date3/5/2021 (Estimated)
OptionableNot Optionable
$3.35
-0.04 (-1.18 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

How has Bio-Path's stock price been impacted by COVID-19?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BPTH stock has decreased by 29.5% and is now trading at $3.35.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bio-Path or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Bio-Path?

Wall Street analysts have given Bio-Path a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Path wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Bio-Path.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings results on Thursday, November, 19th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.03.
View Bio-Path's earnings history.

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

1 Wall Street analysts have issued twelve-month target prices for Bio-Path's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Bio-Path's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 198.5% from the stock's current price.
View analysts' price targets for Bio-Path.

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 117,500 shares, an increase of 2,117.0% from the October 15th total of 5,300 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 0.1 days.
View Bio-Path's Short Interest.

Who are some of Bio-Path's key competitors?

Some companies that are related to Bio-Path include VistaGen Therapeutics (VTGN), Vascular Biogenics (VBLT), Onconova Therapeutics (ONTX), ASLAN Pharmaceuticals (ASLN), Appili Therapeutics (APLIF), Oncternal Therapeutics (ONCT), Daré Bioscience (DARE), Avenue Therapeutics (ATXI), Mereo BioPharma Group (MREO), Monopar Therapeutics (MNPR), Trevi Therapeutics (TRVI), Tenzing Acquisition (TZAC), Elite Pharmaceuticals (ELTP), Seelos Therapeutics (SEEL) and Proteostasis Therapeutics (PTI).
View all competitors.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Canopy Growth (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 71, Pay $490.16k)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 64, Pay $39.58k)
  • Mr. Anthony Price, Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D., MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant
  • Dr. Jeffery Lancet M.D., Consultant
  • Ms. Victoria Lake Rac, Regulatory Consultant

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $3.35.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $15.22 million and generates $40,000.00 in revenue each year. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Bio-Path employs 9 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is www.biopathholdings.com.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.